|
1
|
Troyanov S, Wall CA, Miller JA, Scholey JW
and Cattran DC; Toronto Glomerulonephritis Registry Group. Focal
and segmental glomerulosclerosis: definition and relevance of a
partial remission. J Am Soc Nephrol. 16:1061–1068. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ehrich JH, Geerlings C, Zivicnjak M,
Franke D, Geerlings H and Gellermann J: Steroid-resistant
idiopathic childhood nephrosis: overdiagnosed and undertreated.
Nephrol Dial Transplant. 22:2183–2193. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miroux C, Morales O, Ghazal K, et al: In
vitro effects of cyclosporine A and tacrolimus on regulatory T-cell
proliferation and function. Transplantation. 94:123–131. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kamar N, Allard J, Ader JL and Rostaing L:
Cyclosporine-A-based immunosuppression and renal functional reserve
in organ-transplant patients. Transplant Proc. 36(2 Suppl):
248S–250S. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jang HR, Jung HW, Lee YJ, et al:
Combination treatment with corticosteroid, cyclosporine A, and
mycophenolate in refractory nephrotic syndrome. Clin Nephrol.
75:511–517. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kranz B, Vester U, Büscher R, Wingen AM
and Hoyer PF: Cyclosporine-A-induced nephrotoxicity in children
with minimal-change nephrotic syndrome: long-term treatment up to
10 years. Pediatr Nephrol. 23:581–586. 2008.PubMed/NCBI
|
|
7
|
Group KDIGO. KDIGO Clinical Practice
Guideline for Glomerulonephritis. Kidney Int Suppl. 2:139–274.
2012.
|
|
8
|
Kornberg A, Küpper B, Hommann M and
Scheele J: Introduction of MMF in conjunction with stepwise
reduction of calcineurin inhibitor in stable liver transplant
patients with renal dysfunction. Int Immunopharmacol. 5:141–146.
2005. View Article : Google Scholar
|
|
9
|
Cantarovich M, Tzimas GN, Barkun J,
Deschênes M, Alpert E and Tchervenkov J: Efficacy of mycophenolate
mofetil combined with very low-dose cyclosporine microemulsion in
long-term liver-transplant patients with renal dysfunction.
Transplantation. 76:98–102. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Prytula A, Iijima K, Kamei K, et al:
Rituximab in refractory nephrotic syndrome. Pediatr Nephrol.
25:461–468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tocci MJ and Sigal NH: Recent advances in
the mechanism of action of cyclosporine and FK506. Curr Opin
Nephrol Hypertens. 1:236–242. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jenkins MK, Schwartz RH and Pardoll DM:
Effects of cyclosporine A on T cell development and clonal
deletion. Science. 241:1655–1658. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Singh A, Tejani C and Tejani A: One-center
experience with cyclosporine in refractory nephrotic syndrome in
children. Pediatr Nephrol. 13:26–32. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hamasaki Y, Yoshikawa N, Nakazato H, et
al; for Japanese Study Group of Renal Disease in Children.
Prospective 5-year follow-up of cyclosporine treatment in children
with steroid-resistant nephrosis. Pediatr Nephrol. 28:765–771.
2013.PubMed/NCBI
|
|
15
|
Shehata M, el Nahas M, Barkworth E, Cope
GH and Raftery AT: Localization of PDGF-BB in the juxtaglomerular
cells of cyclosporin-treated rats. Exp Nephrol. 3:173–179.
1995.PubMed/NCBI
|
|
16
|
Shihab FS, Andoh TF, Tanner AM, et al:
Role of transforming growth factor-beta 1 in experimental chronic
cyclosporine nephropathy. Kidney Int. 49:1141–1151. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Feutren G and Mihatsch MJ: Risk factors
for cyclosporine-induced nephropathy in patients with autoimmune
diseases. International Kidney Biopsy Registry of Cyclosporine in
Autoimmune Diseases. N Engl J Med. 326:1654–1660. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Meyrier A: Treatment of idiopathic
nephrotic syndrome with cyclosporine A. J Nephrol. 10:14–24.
1997.PubMed/NCBI
|
